THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION.
Therapy-related myeloid neoplasms (t-MNs) encompass a specific sub-group of myeloid malignancies arising after exposure to radio/cytotoxic agents for the treatment of unrelated diseases. Such malignancies present unique features, including advanced age, high comorbidities burden, and unfavorable...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2023-08-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/5428 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841563931103985664 |
|---|---|
| author | Raffaele Palmieri Ilaria Del Principe Luca Maurillo Adriano Venditti Francesco Buccisano |
| author_facet | Raffaele Palmieri Ilaria Del Principe Luca Maurillo Adriano Venditti Francesco Buccisano |
| author_sort | Raffaele Palmieri |
| collection | DOAJ |
| description |
Therapy-related myeloid neoplasms (t-MNs) encompass a specific sub-group of myeloid malignancies arising after exposure to radio/cytotoxic agents for the treatment of unrelated diseases.
Such malignancies present unique features, including advanced age, high comorbidities burden, and unfavorable genetic profiles. All these features justify the need for a specific diagnostic work-up and dedicated treatment algorithms. However, as new classification systems recognize the unique clinical characteristics exhibited by t-MNs patients, how to assess fitness status in this clinical setting is largely unexplored. Optimizing fitness assessment would be crucial in the management of t-MNs patients, considering that factors usually contributing to a worse or better outcome (like age, comorbidities, and treatment history) are patient-specific.
In the absence of specific tools for fitness assessment in this peculiar category of AML, the aim of this review is to describe all those factors related to patient, treatment and disease that allow planning treatments with an optimal risk/benefit ratio.
|
| format | Article |
| id | doaj-art-95bfb52bd6f44e50ac28dbd25e6b9ba5 |
| institution | Kabale University |
| issn | 2035-3006 |
| language | English |
| publishDate | 2023-08-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-95bfb52bd6f44e50ac28dbd25e6b9ba52025-01-02T23:24:25ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062023-08-0115110.4084/MJHID.2023.051THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION.Raffaele Palmieri0Ilaria Del Principe1Luca Maurillo2Adriano VendittiFrancesco Buccisano3Università di Roma TorvergataUniversità di Roma TorvergataUniversità di Roma TorvergataFrancesco Buccisano Cattedra di Ematologia Fondazione Policlinico Tor Vergata francesco.buccisano@uniroma2.it Phone: +390620903228 Fax: +390620903221 Mobile: +393476280480 Therapy-related myeloid neoplasms (t-MNs) encompass a specific sub-group of myeloid malignancies arising after exposure to radio/cytotoxic agents for the treatment of unrelated diseases. Such malignancies present unique features, including advanced age, high comorbidities burden, and unfavorable genetic profiles. All these features justify the need for a specific diagnostic work-up and dedicated treatment algorithms. However, as new classification systems recognize the unique clinical characteristics exhibited by t-MNs patients, how to assess fitness status in this clinical setting is largely unexplored. Optimizing fitness assessment would be crucial in the management of t-MNs patients, considering that factors usually contributing to a worse or better outcome (like age, comorbidities, and treatment history) are patient-specific. In the absence of specific tools for fitness assessment in this peculiar category of AML, the aim of this review is to describe all those factors related to patient, treatment and disease that allow planning treatments with an optimal risk/benefit ratio. http://www.mjhid.org/index.php/mjhid/article/view/5428t-amlT-mnClinical evaluation |
| spellingShingle | Raffaele Palmieri Ilaria Del Principe Luca Maurillo Adriano Venditti Francesco Buccisano THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Mediterranean Journal of Hematology and Infectious Diseases t-aml T-mn Clinical evaluation |
| title | THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. |
| title_full | THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. |
| title_fullStr | THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. |
| title_full_unstemmed | THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. |
| title_short | THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. |
| title_sort | therapy related myeloid neoplasms considerations for patients clinical evaluation |
| topic | t-aml T-mn Clinical evaluation |
| url | http://www.mjhid.org/index.php/mjhid/article/view/5428 |
| work_keys_str_mv | AT raffaelepalmieri therapyrelatedmyeloidneoplasmsconsiderationsforpatientsclinicalevaluation AT ilariadelprincipe therapyrelatedmyeloidneoplasmsconsiderationsforpatientsclinicalevaluation AT lucamaurillo therapyrelatedmyeloidneoplasmsconsiderationsforpatientsclinicalevaluation AT adrianovenditti therapyrelatedmyeloidneoplasmsconsiderationsforpatientsclinicalevaluation AT francescobuccisano therapyrelatedmyeloidneoplasmsconsiderationsforpatientsclinicalevaluation |